Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 3 Results

Intervention Indication Therapeutic Area Year Actions
Ramucirumab (Cyramza) + capecitabine or 5-FU + cisplatin for gastric cancer of GOJ – treatment naive for palliative chemotherapy 5-Fluorouracil , Capecitabine (Xeloda) , Cisplatin (Platinol) , Ramucirumab (Cyramza) Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Ramucirumab for Advanced Hepatocellular Carcinoma – second line Ramucirumab (Cyramza) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2018 View  |  Download
Ramucirumab in addition to erlotinib for EGFR mutation-positive metastatic non-small-cell lung cancer Erlotinib (Tarceva; erlotinib hydrochloride) , Ramucirumab (Cyramza) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications